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Pivotal Advance: Eosinophil infiltration of solid tumors is an
early and persistent inflammatory host response
Stephania A. Cormier,*,† Anna G. Taranova,‡ Carrie Bedient,‡ Thanh Nguyen,* Cheryl Protheroe,*
Ralph Pero,* Dawn Dimina,‡ Sergei I. Ochkur,‡ Katie O’Neill,* Dana Colbert,*
Theresa R. Lombari,§ Stephanie Constant,¶ Michael P. McGarry,‡ James J. Lee,‡,1
and Nancy A. Lee*,2
Divisions of *Hematology and Oncology and ‡Pulmonary Medicine and §Laboratory Animal Research Core (LARC)
Facility, Mayo Clinic Arizona, Scottsdale; †Department of Biological Sciences, Louisiana State University, Baton
Rouge; and ¶Department of Microbiology and Tropical Medicine, George Washington University, Washington, DC

Abstract: Tumor-associated eosinophilia has been
observed in numerous human cancers and several
tumor models in animals; however, the details surrounding this eosinophilia remain largely undefined and anecdotal. We used a B16-F10 melanoma cell injection model to demonstrate that eosinophil infiltration of tumors occurred from the
earliest palpable stages with significant accumulations only in the necrotic and capsule regions. Furthermore, the presence of diffuse extracellular matrix staining for eosinophil major basic protein was
restricted to the necrotic areas of tumors, indicating that eosinophil degranulation was limited to this
region. Antibody-mediated depletion of CD4ⴙ T
cells and adoptive transfer of eosinophils suggested, respectively, that the accumulation of eosinophils is not associated with T helper cell type
2-dependent immune responses and that recruitment is a dynamic, ongoing process, occurring
throughout tumor growth. Ex vivo migration studies have identified what appears to be a novel chemotactic factor(s) released by stressed/dying melanoma cells, suggesting that the accumulation of
eosinophils in tumors occurs, in part, through a
unique mechanism dependent on a signal(s) released from areas of necrosis. Collectively, these
studies demonstrate that the infiltration of tumors
by eosinophils is an early and persistent response
that is spatial-restricted. It is more important that
these data also show that the mechanism(s) that
elicit this host response occur, independent of immune surveillance, suggesting that eosinophils are
part of an early inflammatory reaction at the site of
tumorigenesis. J. Leukoc. Biol. 79: 1131–1139;
2006.
Key Words: tumor immunology 䡠 cancer 䡠 mice 䡠 B16 melanoma
cells

INTRODUCTION
Galen [1] first noted the association between cancer and inflammation in his writings Opera Omnia almost 2000 years ago.
0741-5400/06/0079-1131 © Society for Leukocyte Biology

During the succeeding millennia, the collective understanding
of cancer-induced inflammatory responses evolved into a hypothesis first presented by Willis [2] that the human body
recognizes and mounts a defensive response against tumors. A
generation later, F. M. Burnet [3] characterized these responses, coining the term “immune surveillance”. Since then,
numerous studies have expanded the details of individual
immune responses to tumors, including the recruitment of a
variety of infiltrating lymphoid and myeloid cells. Moreover,
many individual leukocyte subtypes have been investigated,
and in many cases, the data suggest that they potentially
participate in promoting or retarding tumor progression (reviewed in refs. [4 –10]).
Despite an ever-increasing understanding of anti-tumor immune responses, several logistical problems have faced investigators studying the roles of leukocytes, preventing a comprehensive understanding of the relevant immune responses and
the development of immune-based strategies to combat malignancies. For example, many tumors evade immune surveillance or elicit only nominal immune responses [11–13]. Cancers also often suppress immune responses, quenching otherwise effective defense mechanisms [14 –16]. In addition,
leukocyte infiltrates often vary with tumor type and size, suggesting that immune responses are neither consistent nor static
events [6, 17]. Investigations assessing these issues have led to
the proposal that in addition to immune surveillance, host
recognition of tumors also includes inflammatory responses
[18]. Thus, in addition to specific immune-mediated responses,
tumor sites are often centers of inflammatory reactions, leading
to the recruitment of proinflammatory leukocytes [5, 6, 9, 19,
20].
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Eosinophils have been recognized in cellular infiltrates of
tumors, even in early histological studies of human cancers
[21–25]. Clinical observations have shown that the appearance
of eosinophils in solid tumors is common and occurs in several
tumor types, particularly those of epithelial origin (e.g., colon
and breast tumors; reviewed in refs. [21, 26]). In some studies,
this infiltrate was suggested as a positive, prognostic indicator
of patient survival [27–31]; however, the design of these studies casts doubts on this claim (e.g., the lack of statistical
power), preventing a definitive link between tumor growth and
the presence of eosinophils. Despite the prevailing belief that
eosinophils participate in anti-tumor mechanisms, the role of
these leukocytes in host defenses against tumors is at best
equivocal. Tumor growth clearly occurs despite the presence of
eosinophils, including tumors in animal model systems, in
which the malignant cells express eosinophil-agonist factors
(see, for example, ref. [32]). The limited number of animal
tumor models examined also fuels much of the controversy
associated with eosinophils and tumor responses. For example,
nearly all of the mouse studies examining eosinophils and
eosinophil effector functions during tumorigenesis have used
transfected cell lines modified to provoke defined immune
responses in the recipient mice. In earlier studies, interleukin
(IL)-4 was expressed [33], and in a more recent attempt [34],
melanoma cells were genetically modified to express a specific
antigen (ovalbumin) to elicit T helper cell type 2 (Th2) inflammatory responses in tumor-bearing mice sensitized to this
antigen. The contrived character of these transfected cell models limits their translation to human disease, as it is unclear
from any of these studies whether tumors are capable of recruiting eosinophils without the additional immune modulation
of the tumor cells or the recipient mice. Moreover, the kinetic
and spatial details of this tumor-associated eosinophilia in
these models were often ignored, as eosinophil-specific antibodies for histological detection were unavailable.
The current study defines the parameters surrounding the
recruitment and accumulation of eosinophils in the classical,
well-defined B16 melanoma cell-derived tumor model. These
studies used unmanipulated melanoma cells and wild-type
mice, demonstrating that eosinophil recruitment to tumors was
an early host inflammatory response that occurred, independent of Th2 immune responses. It is interesting that eosinophil
accumulation occurred even in established tumors, and although the cause of this tumor-associated eosinophilia remains
unresolved, evidence is presented, suggesting that the necrotic
regions of tumors release a factor(s) that mediates eosinophil
chemotaxis. Thus, the data presented demonstrate that eosinophil recruitment is spatially restricted to specific regions
within tumors, occurs independent of immune surveillance
mechanisms, and is likely an inflammatory response at the site
of tumorigenesis, promoting an early and persistent host recognition of solid tumors.

MATERIALS AND METHODS
Animals
Recipient mice in melanoma cell injection studies (i.e., C57BL/6J) were
purchased from The Jackson Laboratory (Bar Harbor, ME). All procedures
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were conducted on female mice, 8 –16 weeks of age, maintained in ventilated
microisolator cages, housed within a specific, pathogen-free animal facility,
surveyed by a mixed-bed sentinel mouse program. Protocols and studies
involving animals were conducted in accordance with National Institutes of
Health (NIH; Bethesda, MD) and Mayo Clinic Foundation (Rochester, MN)
institutional guidelines.

Generation of solid tumors
B16-F10 melanoma cells (American Type Culture Collection, Manassas, VA)
were cultured in Dulbecco’s modified Eagle’s medium, supplemented with
10% heat-inactivated fetal calf serum (FCS) and 1% penicillin/streptomycin,
all purchased from Invitrogen (Carlsbad CA). Melanoma cells (5⫻105) were
injected subcutaneously (s.c.) above the right shoulder area of syngeneic
C57BL/6J female mice. The site of injection was monitored daily, and the
resulting solid tumors were allowed to grow until they were palpable (Day 10)
or until the tumor weights averaged ⬃1 g (Day 16).

Histology and immunohistochemical detection
of eosinophils
Mice were killed and tumors harvested for histological analysis, fixing the
tissue overnight at 4°C in 10% formalin prior to embedding in paraffin. Serial
4 m sections throughout the harvested tumors were stained with hematoxylin
and eosin (H&E) or assessed for the presence of eosinophils by immunohistochemistry using a rabbit polyclonal anti-mouse eosinophil major basic protein (MBP) antiserum [35]. Sections stained with biotin-conjugated rabbit
immunoglobulin G (IgG; Sigma-Aldrich, St. Louis, MO) were included as an
isotype control as described earlier [35]. Immunohistochemical staining was
performed with the VIP-Peroxidase detection kit (Vector Laboratories, Inc.,
Burlingame, CA) using a modified version of the protocol supplied by the
manufacturer. Briefly, all slide manipulations were done at room temperature.
Deparaffinized slides were hydrated in 1⫻ phosphate-buffered saline (PBS)
prior to the quenching of endogenous peroxidase activity in the tissue sections
through a 20-min incubation in 0.6% H2O2/80% CH3OH. Quenched slides
were washed in 1⫻ PBS, digested with pepsin (10 min), washed again with 1⫻
PBS, and finally, blocked with 1.5% normal goat serum (30 min). The rabbit
polyclonal anti-mouse MBP antisera was used as a 1:1000 dilution in 1.5%
normal goat serum and incubated with blocked slides for 60 min. Following
three, 5-min rinses with 1⫻ PBS/0.4% Tween-20, the slides were incubated
with a biotinylated goat anti-rabbit secondary antibody, and MBP-specific
antibody binding was visualized as a purple precipitate using the detection
protocol outlined in the manufacturer’s instructions. The MBP-stained sections
were counterstained with 0.1% methyl green in preparation for photomicroscopy, using an Axiotoplan microscope (Carl Zeiss, Obrkochen, Germany). The
density of MBP-positive cells (i.e., eosinophils) within different regions of the
tumors was quantified (cells/mm2) using the image analysis software program
ImagePro Plus (Media Cybernetics, Silver Spring, MD).

Eosinophil-adoptive transfer and confocal
microscopy
Adoptive transfers were performed using blood eosinophils isolated from IL-5
transgenic mice (NJ.1638 mice [36]), back-crossed onto C57BL/6J (n⬎20
generations). Briefly, heparinized blood collected from several donors by
cardiac puncture was layered onto a Percoll E gradient [60% Percoll E
(⫽1.084), 1⫻ Hanks’ balanced saline solution (HBSS), 15 mM Hepes (pH
7.4)] and centrifuged (45 min, 3000 rotations per minute, 4°C). The eosinophilenriched interface was recovered and washed twice in PBS containing 2%
FCS. Eosinophils were isolated using a magnetic cell separation system
(MACS, Miltenyi Biotec, Auburn, CA) through the elimination of contaminating B cells and T cells by positive selection with antibody-conjugated magnetic
beads specific for CD45-R (B220) and CD90 (Thy 1.2), respectively. Cytospin
preparations revealed that the recovered eosinophils were a nearly homogeneous population (⬎98.5% contaminating cells included 1% neutrophils and
0.5% monocytes), which displayed ⬎99% viability via trypan blue exclusion.
The fluorescent marker, carboxylfluorescein diacetate (CFDA), was used to
label purified peripheral blood mouse eosinophils as per the manufacturer’s
instructions (Molecular Probes, Eugene, OR). CFDA-tagged eosinophils, 2 ⫻
107 per animal, were transferred via the peritoneal cavity to tumor-bearing
mice 24 h prior to tumor harvest (i.e., Day 15 of the melanoma cell-injection
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Fig. 1. B16-F10 melanoma cell-derived solid tumors have a defined internal
structure that occurs even in the smallest palpable growths. s.c. injection of
5 ⫻ 105 B16-F10 melanoma cells (Day 0) resulted in the growth of solid
tumors that were palpable by Day 10 and ⬎1 g in mass by Day 16. Day 10 and
Day 16 tumors each revealed a distinct yet similar internal morphology
consisting of necrotic (N) and viable (V) areas surrounded by a fibrotic capsule
region (C). Original scale bar ⫽ 100 m.

protocol). Frozen, serial, 4 m sections were processed for confocal immunofluorescence microscopy using a coverplate system and a rat anti-mouse
eosinophil-associated RNase (Ear) monoclonal antibody (mAb; Clone 32.2.3
[37]). Briefly, at room temperature, sections were washed twice with 1⫻ PBS,
blocked with 1% normal goat serum for 30 min, treated with 1% Chromotrope
2R (Aldrich, Milwaukee, WI) for 30 min, and then rinsed twice with 1⫻
PBS/0.4% Tween-20. Individual slides were incubated with primary rat antimouse Ear antibody (diluted 1:1500) for 1 h at room temperature. Following

Fig. 3. Eosinophils differentially accumulate within the necrotic and capsule
regions of B16-F10 melanoma cell-derived tumors. Quantitative assessments
of eosinophil density (i.e., eosinophils/mm2) were derived from serial sections
of entire tumors. Eosinophils were counted within the necrotic, viable, and
capsule regions from 4 m sections taken every 100 m through each tumor
(n⫽10 mice/group) and expressed as a function of the region’s area. The data
presented represent mean averages ⫾ SEM. All evaluations were performed in
duplicate as independent observer-blinded assessments. *, P ⬍ 0.05; †, P ⬍
0.05, relative to all other groups.

incubation, the slides were washed two times with PBS, and an Alexa-568conjugated goat anti-rat IgG secondary antibody (diluted 1:500; Molecular
Probes) was added and incubated for 30 min at room temperature. Stained
slides were washed twice with 1⫻ PBS/0.4% Tween-20 prior to cover-slipping
with Immu-mount (Themo Electron Corp., Pittsburgh, PA). CFDA and anti-Ear
staining were evaluated using a Zeiss laser-scanning confocal microscope
(LSM 510, Zeiss, Thornwood, NY). Negative control-stained sections revealed
only nominal, nonspecific fluorescent staining of lung tissues.

Antibody-mediated depletion of CD4⫹ T cells
Anti-CD4 mAb (GK1.5) was used to deplete CD4⫹ cells using a modification
of a protocol described previously [38]. Briefly, GK1.5 was administered
[intraperitoneally (i.p.)] to mice (0.5 mg/100 l) 1 week prior to the s.c.
injection of B16-F10 melanoma cells as well as on the day of melanoma cell
injection. Tumor-bearing mice subsequently received additional administrations of GK1.5 antibody every 7 days until tumor harvest. Control groups of
mice were administered nonspecific rat IgG. The ablation of CD4⫹ cells from
mice was confirmed by flow cytometric analysis of splenocytes isolated from
tumor-bearing mice. Spleen samples were disassociated into single cells by
passage through a 40-m mesh and repeated resuspension using a small pore
pipette. Red blood cells were removed from the collected splenocytes with
ammonium chloride lysis buffer, and the recovered white cells were washed in
HBSS containing 2% FCS. Flurochrome-conjugated ␣CD4 [fluorescein isothiocyanate (FITC)] and ␣CD8 [phycoerythrin (PE)] mAb were used for staining (BD Biosciences, San Jose, CA). Analysis was performed on a FACScan
flow cytometer (BD Biosciences) with CellQuest Pro software (BD Biosciences),
gated to exclude fewer than 0.1% of the control cells in the relevant region for
lymphocytes. Splenocytes derived from a tumor-bearing animal receiving nonspecific rat IgG were used to set the gates.
Fig. 2. Eosinophils are recruited to B16-F10 melanoma cell-derived tumors
and localize within defined regions. Immunohistochemistry, using an eosinophil-specific polyclonal rabbit anti-mouse MBP antisera, identified resident
populations of infiltrating eosinophils (dark-purple staining cells) in the necrotic and capsule but not viable regions of Day 10 and Day 16 tumors.
Original scale bar ⫽ 100 m.

Ex vivo transwell assays of eosinophil
chemotaxis assay
Transwell chemotaxis assays were performed using eosinophils isolated and
purified (⬎98%) from the peripheral blood of IL-5 transgenic mice [36] as

Cormier et al. Eosinophil-mediated tumor recognition

1133

described above. Eosinophil chemotaxis was determined via a transwell assay
as described previously [39]. The eosinophil chemotactic character of media
from subconfluent cultures of mouse embryonic stem (ES) and B16-F10
melanoma cell cultures was tested as well as media from postconfluent B16F10 melanoma cell cultures at defined times based on the percentage of dead
cells present (i.e., cells grown beyond confluence in unchanged, nutrientdepleted media). Eotaxin-1 and -2 (PeproTech, Rocky Hill, NJ) were used at
three concentration levels (3 nM, 10 nM, and 30 nM) as positive controls for
migration, and culture media alone was used to determine the assay baseline
(i.e., negative control). Data are expressed as a migration index, which is the
number of cells that migrated in response to a chemotactic factor relative to the
number of cells that migrated in response to media alone. Values presented are
means ⫾ SEM of duplicate determinations conducted on three separate occasions.

Statistical analysis
Unless otherwise noted, all data presented are mean values of the indicated
groups (⫾SEM). Statistical analysis was performed on parametric data using
Student’s t-test with differences between means considered significant when
P ⬍ 0.05.

RESULTS
Subcutaneous injection of melanoma cells leads
to solid tumors with characteristic regions of
viable cells, areas of necrosis, and a surrounding
acellular capsule/stromal layer
Subcutaneous injection of B16-F10 melanoma cells into syngeneic C57BL/6J mice (n⫽10 animals/group) resulted in welldeveloped, solid tumors as early as Day 10 postinjection with
an average weight of 0.106 ⫾ 0.03 g, which increased dramatically by Day 16, resulting in an average weight of 1.02 ⫾
0.17 g. Histological examinations of these tumors (Fig. 1)
revealed progressive growth with distinct regions of necrosis
within viable regions. The small size of 10-day tumors was
associated with a disproportionate amount of viable tissue
relative to areas of necrosis, whereas the larger, 16-day-old
tumors displayed extensive areas of necrosis. All tumors, irrespective of size, were surrounded by a largely fibrous acellular
region (i.e., capsule) separating the tumor from surrounding
host tissue.

(i.e., 3.15%⫾0.64 vs. 3.59%⫾0.58, respectively). The density
of eosinophils present within specific regions of the tumors
(i.e., eosinophils/mm2) demonstrated that a significant eosinophilia occurred within necrotic and capsule regions as compared with areas of viable tumor cells (Fig. 3). Although no
significant difference in eosinophil concentration in the necrotic versus capsule regions was observed at Day 10, the
density of eosinophils was threefold greater in the capsules of
16-day tumors as compared with the necrotic regions. In addition to the identification of infiltrating eosinophils, the antiMBP antisera revealed diffuse extracellular matrix (ECM)
staining within the necrotic areas of the Day-10 and -16 tumors
reflective of degranulation (Fig. 4). It is also noteworthy that
this eosinophil degranulation occurred in all tumors examined
and was not observed in any other regions of the tumors.

Recruitment of eosinophils is an active, ongoing
process occurring throughout tumor growth
The increasing density of eosinophils in regions of Day 16
compared with Day 10 tumors suggested that eosinophils are
continually recruited throughout tumor growth. This hypothesis
was tested by adoptively transferring (i.p.) CFDA-labeled eosinophils (green) into tumor-bearing mice to determine if recruitment was a dynamic event occurring even in established
tumors (Fig. 5). The identification of CFDA-labeled cells as
eosinophils was achieved by costaining the sections with the
eosinophil-specific rat monoclonal anti-mouse Ear antisera (orange), overlapping the two images to display exogenous eosinophils as yellow. The confocal photomicrographs in Figure 5
demonstrate that transfer of eosinophils into tumor-bearing
mice 24 h prior to tumor harvest (i.e., Day 15 of the melanoma
cell-injection protocol) resulted in the accumulation of exogenously derived leukocytes in the necrotic areas of the tumor.

Eosinophil recruitment is an early response to
tumor growth, leading to the differential
accumulation of eosinophils in the capsule and
necrotic areas of solid tumors
Serial sections of tumors were subjected to immunohistochemistry with an eosinophil-specific, rabbit polyclonal, anti-mouse
MBP antisera to identify infiltrating eosinophils and to quantify
the extent and localization of this infiltrate. Despite their size,
even the smallest, palpable tumors (i.e., Day 10) displayed a
robust eosinophil infiltrate, which differentially accumulated in
the necrotic and capsule areas of the tumor with few, if any,
eosinophils observed in the viable areas of the tumors examined (Fig. 2). This pattern remained unchanged as the tumors
grew in size and was observed in tumors at Day 16. It is
interesting that the tumor-associated eosinophilia in these animals occurred without any additional effects on eosinophilopoiesis, such that the peripheral eosinophil counts of tumorbearing mice were unchanged relative to tumor-free controls
1134
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Fig. 4. Eosinophil accumulation within the necrotic areas of tumors is accompanied by degranulation and the release of eosinophil secondary granule
proteins. ECM deposition of MBP (i.e., degranulation) was detected in the
necrotic regions of the B16-F10 melanoma cell-derived tumors by immunohistochemistry with an eosinophil-specific polyclonal rabbit anti-mouse MBP
antisera (i.e., diffuse reddish-purple ECM staining). Original scale bar ⫽
50 m.
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Fig. 5. Adoptive transfer of eosinophils into mice with established tumors demonstrates that eosinophil recruitment to necrotic areas is an active process.
CFDA-tagged peripheral blood eosinophils were transferred (i.p.) to tumor-bearing mice 24 h prior to recovery of 16-day-old tumors. Labeled cells were identified
in the necrotic areas of tumors assessing sections for (A) the presence of cells with the fluorescent CFDA tag (green), which also stained positive with (B) a rat
monoclonal anti-mouse Ear antibody (orange). (C) The colocalization of the fluorescent tag and the antibody stain (i.e., adoptively transferred eosinophils) is shown
as yellow. Original scale bar ⫽ 25 m.

The accumulation of eosinophils in solid tumors
occurred independent of CD4⫹ T cell activities
The presence of eosinophils within the B16-F10 melanoma
cell-derived tumors raises the possibility that tissue accumulation of these leukocytes occurs as a consequence of Th2mediated events orchestrated by CD4⫹ T cells. The dependence of tumor-associated eosinophil infiltration on CD4⫹ T
cells was investigated by depletion of these T cells using an
anti-CD4⫹ antibody (GK1.5; [38]). Fluorescein-activated cell
sorter (FACS) assessment of splenocytes for the presence of
CD4⫹ and CD8⫹ T cells revealed the complete ablation of
CD4⫹ T cells following treatment with GK1.5 with no change
in CD8⫹ cell numbers (Fig. 6A). Eosinophils (i.e., MBP⫹
cells), in the necrotic and capsule regions of tumors from
GK1.5-treated mice, were present in numbers equivalent to
similar regions of tumors derived from control antibody-treated
animals (Fig. 6, B and C), demonstrating that eosinophil infiltration of tumors occurred independent of CD4⫹ T cells.

Conditioned media (CM) derived from
postconfluent cultures of B16-F10 melanoma
cells contain a factor(s) chemotactic
for eosinophils
We performed ex vivo chemotaxis studies with isolated eosinophils and culture CM from B16-F10 melanoma cells to determine if recruitment and accumulation of eosinophils within
tumors were consequences of factors released by the melanoma
cells themselves. CM derived from exponentially growing melanoma cells displayed no eosinophil chemotactic ability. In
addition, CM from another actively dividing cell line, mouse
ES cells, also failed to show any eosinophil chemotactic character. In contrast, CM from postconfluent B16-F10 cultures
possessed eosinophil chemotactic activities in proportion to the
level of cell death observed in the culture. Specifically, Day 5
postconfluent cultures, which were composed of 100% dead
cells, displayed a chemotactic activity that exceeded eotaxin-1
or -2, both physiologically relevant chemokines with eosinophil-agonist activities (Fig. 7). The release of this eosinophil-

chemotactic factor(s) was not limited to melanoma cells, as
postconfluent cultures from a variety of transformed (e.g.,
K1735 [40], Lewis lung carcinoma cells [41], and CMT-93
[42]) and nontransformed (e.g., primary embryonic fibroblasts)
cell lines also displayed chemotactic abilities. In addition,
although the identity of this eosinophil chemoattractant remains unknown, enzyme-linked immunosorbent assays of the
CM from postconfluent B16-F10 cultures failed to detect the
presence of the prominent eosinophil chemotactic CC chemokine receptor 3 ligands (i.e., eotaxin-1 or -2), and migration
studies assessing small molecule mediators with the potential
of eliciting eosinophil chemotaxis (e.g., adenosine [43], uric
acid [44], and cyclophillins [45]) also failed to implicate these
potential candidate pathways (data not shown).

DISCUSSION
The onset and growth of cancers often appear to be a consequence of a tumor’s ability to avoid recognition by the host
immune system and/or elicit immunosuppression (reviewed in
refs. [46 – 48]). The lack of tumor-induced immune responses is
clearly problematic for the host, limiting effective, immunebased defense mechanisms with which to eliminate and/or
attenuate tumor growth. However, in contrast to the lack of
immune-mediated responses, tumor-mediated changes at the
site of growth may lead to the recruitment and accumulation of
proinflammatory leukocytes [17–19]. Thus, although tumors
are not necessarily immunogenic, the sites of growth often
elicit an inflammatory response, which may represent an early
host recognition mechanism of cancer.
The observations presented in this study suggest that the
recruitment and accumulation of eosinophils to tumors are part
of a site-specific, early host-recognition response. The eosinophil infiltration of B16-F10 melanoma cell-derived tumors
occurred in all tumors examined without a concomitant induction of a marrow or peripheral blood eosinophilia beyond
hemostatic baseline levels (i.e., without induced systemicCormier et al. Eosinophil-mediated tumor recognition
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Fig. 6. Eosinophil accumulation in solid tumors
occurred independent of CD4⫹ T cells. (A) Study
protocol of antibody (GK1.5) depletion of CD4⫹
cells. Anti-CD4 mAb was administered (i.p.) 7 days
prior to injection of B16-F10 melanoma cells. Additional administrations were given every 7 days
throughout the protocol. FACS analyses of splenocytes on Day 16, assessing for the presence of CD8
(y-axis) and CD4 (x-axis) cells, showed that CD4⫹
cells are uniquely absent. (B) A representative
H&E-stained section showed the necrotic, viable,
and capsule portions of a Day-16 tumor from a
mouse depleted of CD4⫹ cells, and a serial section
(C) revealed the presence of eosinophils by immunohistochemistry using a rabbit polyclonal antimouse eosinophil MBP antisera (dark-purple staining cells). Despite the loss of CD4⫹ cells, eosinophils were present in necrotic and capsule regions
of these tumors, showing that this infiltration occurred independent of this T cell subtype. Original
scale bar ⫽ 100 m.

immune responses). This eosinophil infiltration also occurred
following the s.c. injection of two other tumorigenic lines
(Lewis Lung and CMT-93; data not shown), suggesting that the
eosinophil infiltrate is a ubiquitous host response to solid tumor
growth. In addition, this robust resident eosinophilia occurred

even in the earliest palpable tumors. Significantly, the eosinophil tumor accumulation occurred without any additional
immunomodulating events, as the injected melanoma cells
were not manipulated to express a unique antigen (e.g., ovalbumin [34]) or an eosinophil-agonist cytokine/chemokine [25, 33,

Fig. 7. Eosinophil migration in response to CM is limited to
stressed and/or dying B16-F10 melanoma cell cultures. Eosinophil migration, in response to CM from dividing, as well as
postconfluent cultures, was assessed using a transwell insert assay
system. The eosinophil-agonist chemokines eotaxin-1 and
eotaxin-2 were used at several concentrations as positive controls
for migration; the data are presented as a chemotactic index
normalized to the eosinophil chemotactic response to media alone;
this baseline migration was consistently 1% of total input cells.
CM from dividing cultures of B16-F10 melanoma cells or mouse
ES cells were unable to elicit eosinophil chemotaxis. In contrast,
the CM from cultures of B16-F10 melanoma cells [expressed as
days (d) postconfluence] displayed significant eosinophil chemotactic activity that increased dramatically with the time postconfluence and the concomitant decrease in culture viability. The
values noted above each histogram indicate the percentage of cell
death observed prior to recovery of culture CM (as determined by
trypan blue exclusion and/or loss of adherence). These data suggest that eosinophil accumulation in tumors is not a consequence
of a factor(s) secreted by growing melanoma cells but instead, may
result from the unique release of a factor(s) by stressed/dying cells
within necrotic areas of tumors. *, P ⬍ 0.05.
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49]. Moreover, the recipient wild-type mice were not allergensensitized/challenged to manipulate peripheral eosinophil
numbers or their state of activation [34].
Several lines of evidence suggest that the B16-F10 melanoma cell-derived tumor itself and/or a host inflammatory
response at the site of tumor growth are eliciting the accumulation of eosinophils. That is, the eosinophil infiltrate is not the
result of acquired immunity or Th2-driven responses, which
are part of larger host tumor surveillance mechanisms: The
infiltration of tumors by eosinophils has been demonstrated in
mice deficient of most acquired immune responses (e.g., in
athymic nude mice [49]); B16 melanoma cells are syngeneic
with the C57BL/6J recipient mice and do not elicit lymphocyte-mediated major histocompatibility complex-associated
immune responses [50]; targeted depletion of all CD4⫹ cell
types from recipient mice did not prevent the development of a
tumor-associated eosinophilia; tumor growth did not induce an
increase in eosinophilopoiesis, leading to an increase in circulating eosinophil numbers. In addition, the accumulation of
eosinophils wasn’t simply an initial inflammatory response to
tumor injection/establishment. Eosinophil-adoptive transfer
showed that eosinophils accumulate even in established tumors, suggesting that their recruitment is an active, site-specific event, which occurs independently of T cell-mediated
responses.
The observation that dead/dying, but not actively dividing, melanoma cells release one or more factors capable of
mediating eosinophil chemotaxis suggests that the areas of
necrosis and not the actively dividing, viable portions of the
tumor may be the source of the factor(s) that result in the
recruitment and accumulation of eosinophils. A cursory
examination of several small molecule mediators released
by stressed/dying cells failed to elicit eosinophil chemotaxis; however, other potential candidates remain to be
examined that may contribute this chemotactic response,
including various arachidonic acid metabolites suggested to
have eosinophil-agonist activities (e.g., cysteinyl-leukotrienes [51], 5-oxo-eicosanoids [52], and lipid mediators such
as platelet-activating factor [53]). Moreover, the observation
that multiple cell types (transformed and nontransformed)
also elicit this response suggests that this may be a more
generalized mechanism mediated by a ubiquitous factor
(e.g., high-mobility group box 1 [54]), which has a broader
importance for eosinophil trafficking beyond recruitment to
tumors. In addition, the ability of necrotic regions to induce
eosinophil recruitment suggests that eosinophils are not
trafficking to tumors as a secondary consequence of factors
released by previously recruited leukocytes (i.e., inflammatory cells recruited prior to eosinophils).
Presumably, eosinophil recruitment occurs by migration
from outside of the tumor through the capsule and viable
regions, as these tumors display little evidence of vascularization, which would permit movement of eosinophils directly to
the necrotic regions from circulation. In this model, the steadystate levels of accumulating eosinophils in each region of the
tumor occurred as a consequence of a specific trafficking
mechanism.

Necrotic regions

Eosinophils accumulate in the necrotic regions first and foremost, as this is the destination of the vectorial movement of
these cells. Although the functionality of this accumulation
remains unresolved, the ability of eosinophils to release copious amounts of vasoactive leukotrienes [55] and potentially
promote localized angiogenesis [56, 57] suggests that this
eosinophilia may represent a physiologic response to localized
hypoxia [58]. This relationship between eosinophils and necrotic regions would also create a positive feedback loop,
which may explain the increased eosinophil accumulation occurring as tumors become larger. That is, eosinophils recruited
to necrotic regions of tumors may expand these areas of necrosis through destructive effector functions (e.g., release of
toxic cationic proteins such as MBP) and increase the release
of a chemotactic factor(s), which in turn, leads to the recruitment of yet more eosinophils.
Viable regions

The small, steady-state levels of resident eosinophils in the
viable regions of the tumors may simply reflect the rapid transit
of eosinophils, or alternatively, the absence of a significant
resident population reflects the lack of stabilizing signals,
prolonging eosinophil survival in these regions.
Capsule regions

The presence of a robust resident population of eosinophils in
the capsule regions likely reflects the partial trapping of eosinophils, which are continually infiltrating from outside of the
tumor as they attempt to move toward the necrotic regions [i.e.,
source of chemotactic factor(s)]. Alternatively, as the growing
tumor crowds and physically perturbs the surrounding host
tissue, the induced stress on these normal cells may lead to the
release of remodeling signals, causing an initial influx of
eosinophils to the tumor site prior to their subsequent response
to the more localized chemotactic signals released by necrotic
regions. This paradigm provides an explanation for our observation that eosinophil effector functions such as degranulation
occur in the necrotic and not the capsule areas of tumors. The
steady-state population of eosinophils in the capsule would not
be expected to be necessarily activated or “functional”, as
these cells would be present only because of an inability to
traverse this region efficiently or because of chemotactic signals released by the normal cells surrounding the growing
tumor. In contrast, the necrotic regions of tumors are the sites
toward which the eosinophils are moving because of a functional demand for eosinophil-mediated activities (i.e., the accumulation of eosinophils in this region is not a random event
leading to the accumulation of “bystander” cells). Therefore,
unlike other regions associated with the tumors, the necrotic
areas promote eosinophil activation and the release of toxic
cationic granule proteins (i.e., degranulation). Furthermore,
eosinophil degranulation in the necrotic regions likely contributes to an overall loss of intact eosinophils from these regions,
suggesting a mechanism leading to the lower steady-state levels observed in regions of necrosis relative to the capsule
regions.
Regardless of the cause of accumulation or the mechanisms
by which eosinophils traffic to tumors, a salient question reCormier et al. Eosinophil-mediated tumor recognition
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mains: What are the consequences of this eosinophil infiltration? Specifically, are eosinophils destructive, cytotoxic effector cells limiting tumor growth as part of a host surveillance
mechanism, or do the infiltrating eosinophils facilitate tumor
growth by remodeling and immunoregulation of the tumor
microenvironment? That is, do eosinophils promote the necrotic areas of tumors, which in turn, limits the rate of tumor
growth, or are eosinophils recruited to tumors as a consequence
of induced host inflammatory/tissue-remodeling responses?
The absolute number of eosinophils in the necrotic areas of
tumors, although significant, is relatively small (e.g., compared
with macrophages [59]), which may limit the cytotoxic (i.e.,
destructive) effects potentially mediated by these granulocytes.
In contrast, eosinophils are capable of elaborating numerous
cytokines and growth factors that have agonist activities on
remodeling events and immune responses (reviewed in ref.
[60]) and have been linked to wound-healing [61], each consistent with hypotheses linking the induced recruitment to the
necrotic areas of tumors to larger tissue-remodeling mechanisms.
The difficulties defining the role of these granulocytes in
cancers occur because of the nominal character of the eosinophil infiltrate and the lack of studies of sufficient statistical
power, demonstrating a link between eosinophils and modulations of tumor growth (see, for example, refs. [22, 28, 31, 62]).
Irrespective of these difficulties, tumors arise and grow despite
the presence of an eosinophil infiltrate, and correlations with
tumor growth have tended not to be linear (e.g., ref. [63] vs. ref.
[34] vs. ref. [25]). Moreover, exceptions to the rule exist with
apparent dissociations between the presence of eosinophils
(and/or the lack thereof) and rates of tumor onset/growth (e.g.,
ref. [64]). In addition, all of the mouse studies attempting to
causatively link the presence of eosinophils and modulations of
tumor growth used genetically engineered the tumor cells [33,
49, 64, 65] and/or immunized recipient mice to recognize the
tumor cells [34], thus promoting the tumor as a target of Th2
inflammatory responses (i.e., an induced immune response vs.
an elicited inflammatory response). Unfortunately, the narrow
character of the models used as well as potential of pleiotropic
effects mediated by the induction of contrived immune responses limit the usefulness of these approaches. However, the
demonstration here that eosinophil infiltration is spatially restricted, even in the smallest tumors, and occurs independent
of acquired immune responses suggests that this recruitment is
part of an early host recognition of unique regional heterogeneities at the sites of tumorigenesis. It is more important that
the understanding of the circumstances surrounding this tumor-associated eosinophil infiltrate provides a unique opportunity to define relevant effector functions that may represent
novel, therapeutic options to modulation tumor onset/growth.
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